Dr. Reddy's Laboratories Ltd.
- Country
- 🇮🇳India
- Ownership
- Public
- Established
- 1984-02-24
- Employees
- 27K
- Market Cap
- -
- Website
- http://www.drreddys.com
Clinical Trials
14
Trial Phases
4 Phases
Drug Approvals
13
Drug Approvals
Atomoxetine Hydrochloride Capsules
- Product Name
- 盐酸托莫西汀胶囊
- Approval Number
- 国药准字HJ20220059
- Approval Date
- Jun 30, 2022
Atomoxetine Hydrochloride Capsules
- Product Name
- 盐酸托莫西汀胶囊
- Approval Number
- 国药准字HJ20220060
- Approval Date
- Jun 30, 2022
Atomoxetine Hydrochloride Capsules
- Product Name
- 盐酸托莫西汀胶囊
- Approval Number
- 国药准字HJ20220062
- Approval Date
- Jun 30, 2022
Atomoxetine Hydrochloride Capsules
- Product Name
- 盐酸托莫西汀胶囊
- Approval Number
- 国药准字HJ20220061
- Approval Date
- Jun 30, 2022
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
News
FDA Approves Journey Medical's Emrosi™ for Rosacea Treatment
Journey Medical's Emrosi™ (minocycline hydrochloride extended-release capsules, 40 mg) has received FDA approval for treating inflammatory lesions of rosacea in adults.
Journey Medical's Emrosi Receives FDA Approval for Rosacea Treatment
The FDA has approved Journey Medical's Emrosi (minocycline hydrochloride extended-release capsules, 40 mg) for treating inflammatory lesions of rosacea in adults.
FDA Approves Emrosi (Minocycline Hydrochloride) for Rosacea Treatment
The FDA has approved Emrosi (minocycline hydrochloride) for treating inflammatory lesions of rosacea in adults, offering a new treatment option.
Dr. Reddy's Launches First-in-Class Drug, BixiBat (Elobixibat), for Chronic Constipation in India
Dr. Reddy's Laboratories has launched Elobixibat, a novel drug for treating chronic constipation, under the brand name BixiBat in India.
Journey Medical Submits NDA to FDA for DFD-29 Rosacea Treatment
Journey Medical has submitted a New Drug Application (NDA) to the FDA for DFD-29 for treating rosacea, specifically erythema and inflammatory lesions.